Articles tagged "Mycophenolate mofetil"

2022 American Transplant Congress
Kidney Transplant Recipients with Diabetic Mellitus Demand Larger Doses of Mycophenolate Mofetil
D. Takamoto, H. Sasaki, S. Harada, Y. Takada, H. Harada, T. Tsujimoto
Kidney transplant surgery and Urology, Sapporo City General Hospital, Sapporo, Japan
*Purpose: To monitor blood concentration of immunosuppressants, therapeutic drug monitoring (TDM) is required at any point after kidney transplantation (KT) to prevent kidney graft from…
2022 American Transplant Congress
Assessing Proportion of Days Covered (PDC) of Mycophenolate (MCP) Prescriptions in Post Kidney Transplant (KT) Recipients as a Predictor of Clinical Outcomes
K. Sandlin¹, T. Sam¹, N. Wilson¹, A. Yango², B. Fischbach³, A. Dao¹
¹Pharmacy, Baylor University Medical Center, Dallas, TX, ²Baylor All Saints Medical Center, Dallas Nephrology Associates, Fort Worth, TX, ³Baylor University Medical Center, Dallas Nephrology Associates, Dallas, TX
*Purpose: Nonadherence to medications following KT is a risk factor for adverse outcomes. PDC is an objective measure of adherence obtained through retail prescription records…
2021 American Transplant Congress
ABCC2 Haplotypes Associations to Mycophenolic Acid Pharmacokinetics in Stable Renal Transplant Recipients
K. Tornatore¹, D. Brazeau², C. Meaney³, J. Consiglio⁴, A. Gundroo⁵, S. Chang⁶, G. Wilding⁴, L. Cooper³
¹Pharmacy Practice, School of Pharmacy; University at Buffalo- SUNY, Buffalo, NY, ²Pharmacy Practice, Marshall University, Huntington, WV, ³Pharmacy Practice, School of Pharmacy; University at Buffalo, Buffalo, NY, ⁴Biostatistics, School of Public Health; University at Buffalo, Buffalo, NY, ⁵Medicine, School of Medicine; Ohio State University, Columbus, OH, ⁶Medicine, School of Medicine; University at Buffalo, Buffalo, NY
*Purpose: Mycophenolic acid (MPA), exhibits interpatient pharmacokinetic (PK) variability attributed to enterohepatic circulation of the glucuronide metabolite (MPAG) to MPA. This is mediated by multidrug…
2021 American Transplant Congress
Dietary Intake and Mycophenolate Mofetil-related Diarrhea Following Kidney Transplantation
G. Onyeaghala¹, L. Teigen², B. Guo², Y. Doronin¹, M. Al-Kofahi², B. Wu², W. Guan², C. Staley², S. Riad², A. Matas², R. Remmel², W. Oetting², C. Dorr¹, P. Jacobson², A. Israni¹
¹Nephrology, Hennepin Healthcare Research Institute, Minneapolis, MN, ²University of Minnesota, Minneapolis, MN
*Purpose: The treatment of Mycophenolate mofetil (MMF) related diarrhea in kidney transplants recipients involves providing lower MMF doses more frequently to maintain the same daily…
2021 American Transplant Congress
Tolerability of Mycophenolate Mofetil in Elderly Kidney Transplant Recipients: A Retrospective Cohort Study
S. Witek¹, G. Malat², D. Sawinski², C. Sammons², C. LaFratte¹, A. Forte¹, R. Samudralwar¹, S. Lyle¹, J. Rashid¹, J. Trofe-Clark²
¹Dept of Pharmacy, Hospital of the Univ of Pennsylvania, Philadelphia, PA, ²Penn Transplant Institute, Hospital of the Univ of Pennsylvania, Philadelphia, PA
*Purpose: Optimal immunosuppression in elderly kidney transplant recipients (KTRs) is not well-defined, with MMF being poorly tolerated at standard doses. This study aims to compare…
2020 American Transplant Congress
Oral versus Intravenous Mycophenolate Mofetil Administration: A Single Center Experience on Incidence of Acute Kidney Injury
P. Chung¹, K. Forrester², S. Ganesh¹
¹Division of Pulmonary Critical and Sleep Medicine, University of Southern California, Los Angeles, CA, ²Department of Clinical Pharmacy, University of Southern California School of Pharmacy, Los Angeles, CA
*Purpose: Mycophenolate mofetil (MMF) is one of the main immunosuppressive medications given in lung transplantation (LTx). It is given orally (PO) or intravenously (IV). In…
2020 American Transplant Congress
A Novel Formula to Determine Optimal Immunosuppression in Renal Transplant Recipients Treated with Tacrolimus and Mycophenolate Mofetil: Towards Individualized Immunosuppression
O. Pankewycz¹, M. Laftavi¹, E. Onan², D. Rucker¹, D. Wang¹, K. Bhuta¹, R. Gruessner³, A. Gruessner³
¹SUNY, Upstate Medical University, Syracuse, NY, ²Cukurova University, Adana, Turkey, ³SUNY, Downstate Medical University, New York, NY
*Purpose: Tacrolimus (TAC) and mycophenolic acid (MPA) remain the most commonly used drug combination for kidney transplant immunosuppression. Adequate drug dosing is challenging due to…
2020 American Transplant Congress
The Role of mTOR Inhibitors on Cardiovascular Aging in Renal Transplanted Patients with Chronic Graft Dysfunction
G. Castellano¹, B. Infante¹, P. Pontrelli¹, R. Franzin¹, F. Rascio¹, C. Prisciandaro², L. Gesualdo¹, N. Coviello³, G. Grandaliano³, G. Stallone³
¹Emergency and Organ Transplantation, University of Bari, Bari, Italy, ²University of Foggia, Foggia, Italy, ³Emergency and Organ Transplantation, University of Foggia, Foggia, Italy
*Purpose: Chronic Kidney Disease (CKD) is strongly associated with increased circulatory complications that can lead to accelerated cardiovascular aging. During CKD, persistent oxidative stress triggered…
2020 American Transplant Congress
Low Mycophenolic Acid Levels are Associated with More Inflammation on 1 Year Protocol Biopsies and Lower Graft Survival in Kidney Transplant Recipients
J. Huskey, G. Mour, M. Ryan, S. Nair, M. Smith, R. Heilman
Mayo Clinic Arizona, Phoenix, AZ
*Purpose: Data is limited on the association of Mycophenolic Acid (MPA) concentration on protocol kidney transplant biopsies. Our aim is to compare clinical outcomes and…
2020 American Transplant Congress
Outcomes Associated with Mycophenolate Weight-Based Dosing in Varying Immunologic Risk Kidney Transplant Recipients
A. A. Al-Bahou, A. R. Webb, M. Bloxam, L. J. Bowman Anger, R. S. Baliga, A. J. Brueckner
Tampa General Hospital, Tampa, FL
*Purpose: Mycophenolate acid (MPA) is traditionally dosed in kidney transplant recipients (KTR) using the FDA-approved fixed dosing which is irrespective of patient-specific variables such as…